Clinical trials: Bortezomib
Multiple Myeloma
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
This is a Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade® [bortezomib] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.
- Trial name
- NCT00555906
- Testing
- Bortezomib, Dexamethasone, PD 0332991
- Where
- 19 sites in United States, Czechia and 1 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Multiple Myeloma
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and…
- Trial name
- NCT02773030
- Testing
- CC-220, Dexamethasone, Daratumumab
- Where
- 162 sites in United States, Australia and 9 more
- Volunteers
- 466 people
- Sponsor
- Celgene
Amyloidosis
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: daratumumab + immediate VCd treatment and Arm B: daratumumab +…
- Trial name
- AQUARIUS (NCT05250973)
- Testing
- Daratumumab, Cyclophosphamide, Bortezomib
- Where
- 46 sites in United States, Canada and 8 more
- Volunteers
- 151 people
- Sponsor
- Janssen Research & Development, LLC
Chemotherapy-induced Peripheral Neuropathy
Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer, bortezomib for multiple myeloma, oxaliplatin-based regimens for colorectal cancer…
- Trial name
- EPIPHANY (NCT03997981)
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Disarm Therapeutics
Amyloidosis
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)
The purpose of this study is to evaluate the efficacy and safety of SCTC21C plus cyclophosphamide, bortezomib and dexamethasone (VCd) compared with VCd alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis…
- Trial name
- NCT07388602
- Testing
- SCTC21C, Bortezomib, Dexamethasone
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sinocelltech Ltd.
Multiple Myeloma
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Study for the outcome and safety of individualized busulfan dosing with bortezomib for patients preparing for a second stem cell transplant to treat multiple myeloma.
- Trial name
- NCT01009840
- Testing
- IV busulfan, bortezomib, Autologous Hematopoietic Stem Cell Transplant (HSCT)
- Where
- 13 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Multiple Myeloma
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
The non-interventional study SEATTLE aims to answer open scientific questions regarding QoL and tolerability/safety and AE management of selinexor as well as effectiveness and dosing in clinical routine.
- Trial name
- SEATTLE (NCT05954780)
- Testing
- Selinexor
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- iOMEDICO AG
Multiple Myeloma and Plasma Cell Neoplasm
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Radioactive substances, such as samarium 153, may release radiation as it breaks down and kill cancer cells. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00316940
- Testing
- bortezomib, samarium Sm 153 lexidronam pentasodium
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
One purpose of this study is to evaluate the effectiveness and safety in long term treatment for patients who completed preceding phase I/II study.
- Trial name
- NCT00216697
- Testing
- bortezomib
- Volunteers
- 13 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade) plus…
- Trial name
- BOSTON (NCT03110562)
- Testing
- Selinexor, Bortezomib, Dexamethasone
- Where
- 157 sites in United States, Australia and 19 more
- Volunteers
- 402 people
- Sponsor
- Karyopharm Therapeutics Inc
Multiple Myeloma
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with…
- Trial name
- NCT02188368
- Testing
- POM, Steroids, PLD
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
The primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of rapamycin (mTOR) inhibitor, a protease…
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- NCT01088048
- Testing
- Idelalisib, Rituximab, Bendamustine
- Where
- 11 sites in United States
- Volunteers
- 241 people
- Sponsor
- Gilead Sciences
Newly Diagnosed Multiple Myeloma
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
The goal of this clinical study iMMagine-6 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus autologous stem cell transplant in participants with newly diagnosed multiple myeloma (NDMM).
- Trial name
- iMMagine-6 (NCT07903506)
- Testing
- Anitocabtagene Autoleucel, Isatuximab, Bortezomib
- Volunteers
- 750 people
- Sponsor
- Kite, A Gilead Company
Multiple Myeloma
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma to combination regimens of melflufen with currently approved agents.
- Trial name
- ANCHOR (NCT03481556)
- Testing
- Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib
- Where
- 16 sites in United States, Czechia and 2 more
- Volunteers
- 56 people
- Sponsor
- Oncopeptides AB
Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
This study is designed to assess the effectiveness of the combination of Panobinostat plus Bortezomib and Dexamethasone in patients with relapsed and bortezomib refractory Multiple Myeloma.
- Conditions
- Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse
- Trial name
- MACS1271 (NCT01083602)
- Testing
- panobinostat, bortezomib, dexamethasone
- Where
- 13 sites in United States
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
The purpose of this study is to determine safety and the maximum tolerated dose (MTD) of GRN163L and Velcade with and without Decadron when administered to patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00718601
- Testing
- Imetelstat Sodium (GRN163L)
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Geron Corporation
Multiple Myeloma
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
Phase Ib, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of GSK2110183 dosed in combination with bortezomib and dexamethasone in multiple myeloma (MM)…
- Trial name
- PKB115125 (NCT01428492)
- Testing
- GSK2110183, Bortezomib, Dexamethasone
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 90 people
- Sponsor
- Novartis
Relapsed Refractory Multiple Myeloma
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd [daratumumab, carfilzomib, and dexamethasone], DPd [daratumumab…
- Trial name
- DURGA-4 (NCT07391657)
- Testing
- AZD0120, Daratumumab, Carfilzomib
- Where
- 143 sites in United States, Australia and 13 more
- Volunteers
- 508 people
- Sponsor
- AstraZeneca
Multiple Myeloma
Trial of Romidepsin and Bortezomib for Multiple Myeloma
This is a phase II, open-label, multicenter, dual-strata study designed to evaluate the efficacy and safety of IV romidepsin given in combination with IV bortezomib for multiple myeloma (MM) patients with refractory or relapsed…
- Trial name
- NCT00765102
- Testing
- Bortezomib, Romidepsin
- Where
- 12 sites in United States
- Volunteers
- 32 people
- Sponsor
- Celgene
Multiple Myeloma, Hematological Neoplasms
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
The main purpose of this study is to evaluate safety and effectiveness of the treatment of multiple myeloma with bortezomib in daily practice in the Netherlands.
- Trial name
- NCT00440765
- Testing
- bortezomib
- Where
- 44 sites in Netherlands
- Volunteers
- 331 people
- Sponsor
- Janssen-Cilag B.V.